CVE:NDVA

Indiva Competitors

C$0.42
+0.01 (+2.47 %)
(As of 05/6/2021 01:37 PM ET)
Add
Compare
Today's Range
C$0.41
C$0.43
50-Day Range
C$0.37
C$0.56
52-Week Range
C$0.19
C$0.74
Volume75,723 shs
Average Volume380,823 shs
Market CapitalizationC$55.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Indiva (CVE:NDVA) Vs. WMD, NINE, ASP, FLWR, RX, and MDP

Should you be buying NDVA stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Indiva, including WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), BioSyent (RX), and Medexus Pharmaceuticals (MDP).

Indiva (CVE:NDVA) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and WeedMD, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indiva00103.00
WeedMD02002.00

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. WeedMD has a consensus target price of C$0.58, indicating a potential upside of 88.17%. Given WeedMD's higher probable upside, analysts plainly believe WeedMD is more favorable than Indiva.

Profitability

This table compares Indiva and WeedMD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IndivaN/AN/AN/A
WeedMDN/AN/AN/A

Earnings & Valuation

This table compares Indiva and WeedMD's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24
WeedMDC$27.21 million2.81C$-21,702,912.00C($0.09)-3.52

Indiva has higher earnings, but lower revenue than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Indiva, indicating that it is currently the more affordable of the two stocks.

Summary

Indiva beats WeedMD on 5 of the 8 factors compared between the two stocks.

Indiva (CVE:NDVA) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indiva00103.00
Delta 9 Cannabis0000N/A

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, equities research analysts plainly believe Indiva is more favorable than Delta 9 Cannabis.

Profitability

This table compares Indiva and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IndivaN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Earnings & Valuation

This table compares Indiva and Delta 9 Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07

Delta 9 Cannabis has higher revenue and earnings than Indiva. Indiva is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Indiva on 4 of the 7 factors compared between the two stocks.

Indiva (CVE:NDVA) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Earnings & Valuation

This table compares Indiva and Acerus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24
Acerus PharmaceuticalsC$1.09 million70.86C$-56,890,756.00C($0.04)-1.35

Indiva has higher revenue and earnings than Acerus Pharmaceuticals. Indiva is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and Acerus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indiva00103.00
Acerus Pharmaceuticals0000N/A

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, equities research analysts plainly believe Indiva is more favorable than Acerus Pharmaceuticals.

Profitability

This table compares Indiva and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IndivaN/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Summary

Indiva beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

The Flowr (CVE:FLWR) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares The Flowr and Indiva's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrC$7.51 million13.00C$-343,678,650.00C($0.95)-0.28
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24

Indiva has higher revenue and earnings than The Flowr. Indiva is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for The Flowr and Indiva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr0000N/A
Indiva00103.00

The Flowr presently has a consensus price target of C$0.88, indicating a potential upside of 227.16%. Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given The Flowr's higher probable upside, equities analysts plainly believe The Flowr is more favorable than Indiva.

Profitability

This table compares The Flowr and Indiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
IndivaN/AN/AN/A

Summary

Indiva beats The Flowr on 4 of the 7 factors compared between the two stocks.

BioSyent (CVE:RX) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares BioSyent and Indiva's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSyentC$22.33 million4.41C$3.68 millionC$0.2926.72
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24

BioSyent has higher revenue and earnings than Indiva. Indiva is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioSyent and Indiva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSyent02002.00
Indiva00103.00

BioSyent presently has a consensus price target of C$7.00, indicating a potential downside of 9.68%. Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given Indiva's stronger consensus rating and higher probable upside, analysts plainly believe Indiva is more favorable than BioSyent.

Profitability

This table compares BioSyent and Indiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSyentN/AN/AN/A
IndivaN/AN/AN/A

Medexus Pharmaceuticals (CVE:MDP) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Medexus Pharmaceuticals and Indiva's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.27C$-34,573,801.00C($1.81)-3.99
IndivaC$7.92 million7.05C$-17,223,168.00C($0.13)-3.24

Indiva has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Indiva, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Medexus Pharmaceuticals and Indiva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
Indiva00103.00

Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, analysts plainly believe Indiva is more favorable than Medexus Pharmaceuticals.

Profitability

This table compares Medexus Pharmaceuticals and Indiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
IndivaN/AN/AN/A

Summary

Indiva beats Medexus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.


Indiva Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WMD
WeedMD
1.3$0.31+1.6%C$95.35 millionC$27.21 million-3.52
NINE
Delta 9 Cannabis
1.1$1.03+2.9%C$89.36 millionC$12.87 million19.07Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05+0.0%C$76.88 millionC$1.09 million-1.35Upcoming Earnings
News Coverage
FLWR
The Flowr
1.0$0.27+1.9%C$70.01 millionC$7.51 million-0.28Gap Up
RX
BioSyent
0.8$7.75+3.9%C$64.81 millionC$22.33 million26.72Gap Up
MDP
Medexus Pharmaceuticals
0.6$7.22+2.8%C$38.66 millionC$108.29 million-3.99
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.51+5.3%C$38.57 millionC$21.61 million7.40Upcoming Earnings
News Coverage
VIR
Viridium Pacific Group
0.7$0.38+5.3%C$37.54 millionC$1.09 million-2.97Gap Up
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29+7.0%C$36.73 millionN/A-2.61News Coverage
Gap Down
IN
InMed Pharmaceuticals
0.6$4.26+5.6%C$36.23 millionN/A-2.40Upcoming Earnings
News Coverage
Gap Down
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.10+5.3%C$21.51 millionC$8.50 million-0.27Gap Down
EVE
Eve & Co Incorporated
1.0$0.29+3.4%C$21.32 millionC$2.84 million-0.91Upcoming Earnings
SUGR
SugarBud Craft Growers
0.7$0.05+0.0%C$11.81 millionC$66,906.00-0.03Gap Down
NU
NeutriSci International
0.5$0.17+6.1%C$8.65 millionC$69,626.00-12.69
AQS
Aequus Pharmaceuticals
0.9$0.17+3.0%C$6.03 millionC$2.59 million-15.00Gap Up
LBL
Lattice Biologics
0.5$0.05+0.0%C$4.67 millionC$2.24 million-2.37
THCX
(THCX.V)
0.6$5.30+6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00News Coverage
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.